Introduction

Recurrent pregnancy loss (RPL) is defined as two or more consecutive miscarriages before gestation week 22. It has been estimated to be prevalent in approximately 5% of clinically diagnosed pregnancies (1, 2). An overlap etiology and a number of collaborative pathologies were shown for infertility and RPL (3). Although, the risk of RPL increases in the women who are conceived with assisted-reproductive technology (ART) (4). Infertile females experience some psychological problems, including poor quality of life, depression, anxiety, sexual dysfunction function, and marital dissatisfaction (5-7). A recent meta-analysis reported 44.32% depression prevalence in the infertile women (8). Also, infertile women are at higher risk of psychological problems than infertile men (9). Women with RPL suffer from many psychiatric morbidity such as depression, anxiety, complicated grief, and suicide (10). Also, the psychiatric morbidity of infertility may be exacerbated by the RPL (11, 12).

Whilst the evidence for the effect of psychotherapy and pharmacotherapy in the mental health improvement of infertile women is robust, support for their use in infertile women with RPL is sparse. Most research has focused
only on the infertile women who experiencing depression after in vitro fertilization (IVF) failure (13), while few studies have evaluated psychotherapy for depressed infertile women with RPL. To the best of our knowledge, no randomized controlled trial study has explored the effect of psychotherapy for women with RPL; it is unclear whether these findings can be generalized to depressed women with RPL. Nakano et al. (14) reported that cognitive behavioral therapy (CBT) reduced anxiety or depression scores in the 14 women with RPL. Patel et al. (15) reported that mindfulness psychotherapy improved the emotional adjustment in an infertile couple with RPL. Also, some research reported that CBT was useful for patients with a single perinatal loss (16, 17). Although, some research has proposed pharmacotherapy during pregnancy as a risk factor of pregnancy loss (18, 19). There are studies that recommended preconception counseling by psychologist/ psychiatrists or antidepressants treatment for RPL women with severe depression (20, 21). To our knowledge, no study has been published to date that compare the effectiveness of psychotherapy and pharmacotherapy for depression treatment in the women with RPL.

We designed this study to investigate the effect of psychotherapy and pharmacotherapy in RPL women to compare the effect of the two methods of depression treatment in women with RPL. To the best of our knowledge, this is the first three arm randomized controlled trial that compares the effectiveness of CBT with sertraline for the treatment of depression in the infertile women with RPL. The hypotheses of the study were to examine: i. Whether CBT or sertraline is superior than usual care in reducing the score of depression in depressed infertile women with RPL, ii. Whether CBT or sertraline is superior than usual care in lowering the score of anxiety or infertility stress of depressed infertile women with RPL, iii. Which approach, pharmacotherapy or psychotherapy, is superior for mitigating the symptoms of depression, anxiety, and infertility stress among depressed infertile women with RPL.

Materials and Methods

Study type, setting, and duration

A triple-arm parallel-group randomized controlled trial design was conducted from November 2016 to December 2019 in the Fatemeh Zahra Infertility and Reproductive Health Research Center (Mazandaran, Iran), a single university-affiliated IVF center. The trial protocol was approved by the Ethics Committee of Babol University of Medical Sciences, Mazandaran, Iran and was registered in the Iranian Registry of Clinical Trials (IRCT201304045931N3). A written informed consent was obtained before the participants.

Study participants and procedure

All participants were recruited from Recurrent Abortion Clinic of the center Fatemeh Zahra Infertility and Reproductive Health Research Center. Eligibility criteria were included: i. Two or more consecutive miscarriages, ii. At least 5 years of education, iii. 18-40 years of age, iv. Meeting the criteria for probable diagnosis of depression with interview using the Structured Clinical Interview for DSM-5 Disorders (SCID-5-CV), v. Not undergoing fertility treatment until 6 months afterward. The participants were excluded if through clinical interviewing, the psychologist reported: i. Diagnosis of severe depression, bipolar disorders, schizophrenia, or suicide, ii. Having psychotherapy in the last three months, and current use of antidepressants. The excluded patients who suffered from severe mental disorders were referred to a psychiatrist to receive a suitable treatment.

A midwife assessed the inclusion criteria for the patients. If the patients met the inclusion criteria, they were invited to study and completed the demographic questionnaire. Women with initial eligibility in primary assessment were referred to our psychologist to receive a face-to-face interview based on Structured Clinical Interview for DSM-5 Disorders (SCID-5-CV) (22). All participants completed three questionnaires, including the Beck Depression Inventory, second edition (BDI-II), Fertility Problem Inventory (FPI), and State-Trait Anxiety Inventory Form Y (STAI-Y) at baseline, 10-weeks post-trial, and three months of follow-up.

Sample size calculation

Available sampling was performed on the infertile women who referred to our center. As we could not find any research comparing the efficacy of CBT and sertraline on the infertile women with RPL, power calculation was performed based on published RCT of CBT and other pharmacotherapies in the infertile women (14, 23). Also, we conducted a pilot study to calculate the differences between the three groups of the study. To detect the smallest differences, 2.5 on the BDI-II, the minimum sample size for each group (α=0.05, power of 80%) was 16 participants. Thus, we recruited a minimum volunteer of 60 participants, with an attrition risk of 20%.

Randomization

Sixty depressed infertile women with RPL were divided randomly into three groups; pharmacotherapy with sertraline (n=20), psychotherapy with CBT (n=20), and a usual care as control group (n=20). Randomization was completed by an independent midwife according to 1:1:1 ratio using a computer random number generator. Also, allocation randomization was done using sequentially numbered sealed opaque envelopes and concealed from the researcher. The midwife assigned the participants manually and informed them via phone call. One of the study coordinators who was unaware of the trial allocation or the recruitment of the participants, evaluated the treatments.

Study interventions

Psychotherapy group

This experimental group received CBT enhanced with
Treatment of Depression in Infertile Women with RPR

Functional Analytic therapy (FACBT). Kohlenberg and Tsai (24) introduced FACBT to enhance the focus on the client-therapist relationship and to gain a broader insight into the cause of the problem and treatment. This model includes seven specific enhancement techniques the CBT therapist can use to address the needs of the patients. The seven techniques include expanded rationale, greater use of the patient-therapist relationship, employing case conceptualization, noticing and recognizing Clinically Relevant Behavior (CRB), asking questions to evoke CRBs, increasing self-awareness to detect CRBs, and applying modified thought records.

A female psychologist, who was expert in infertility branch, conducted the sessions. Psychotherapy was conducted in ten group sessions (90 minutes each) over 10 weeks. Each group consisted of 10 participants. The psychotherapy treatment was based on FACBT (24) as well as five domains of specific infertility stress (25). Table 1 summarized the contents of the sessions.

**Pharmacotherapy group**

The patients were visited at baseline as well as 2, 6, 10, 16, and 22 weeks post-trial for adjusting the medication and recording the symptoms plus adverse events. Also, there were optional supplementary visits or telephone contacts at any time.

Sertraline (Abidi Pharmaceutical Co., Tehran, Iran) treatment was begun at 50 mg/day. Dose changes were based on the response and side effects. If the symptom reduction was achieved, patients continued the initial dose of the sertraline. However, if the symptoms were not mitigated, the dose could gradually be raised to a maximum of 200 mg/day.

**Usual care group**

Participants of this group received usual care of the infertile without any psychological support.

**Study outcomes**

**Primary outcomes**

**Beck Depression Inventory, second edition**

This scale is a 21-item self-report inventory measuring the severity of depression. Each item is scored on a four-point Likert scale, ranging from 0 to 3. Total scores range 0-63 with higher scores indicate more severe depressive symptoms (26). We used Persian validated BDI-II (27). The Persian version of the BDI-II had high internal consistency (Cronbach’s alpha=0.87 for) and acceptable reliability of test-retest (r=0.74).

**Fertility problem inventory**

This scale was developed by Newton to assess infertility stress (27). It consists of 46 questions. Each item is scored on a six-point Likert scale, ranging from 1 (strongly disagree) to 6 (strongly agree). Some items have reversed scores. The total score of FPI ranges from 46 to 276, where higher scores indicate higher levels of infertility stress. The FPI includes five subscales: social concern (worry about comments of family or friend about her infertility), sexual concern (reduction or difficulty of sexual arousal or enjoyment), relationship concern (worry of talking about infertility with relatives or friends), rejection of parenthood (negative view of life without child), and the need for parenthood (considering parenting as essential goal of life) (25). We used the Persian validated FPI. The validity of the Persian version of FPI was high for all domains (Cronbach’s alpha coefficient 70%) (28).

**State-Trait Anxiety Inventory Form Y**

This scale that first developed by Spielberger et al. (29), is one of the most widely used instruments for capturing anxiety. The scale provides two different components of anxiety: state and trait. This study used the anxiety state component that includes 20 items answered on a 4-point Likert scale. The possible scores range from 20 to 80. We used Persian validated STAI-Y. The Cronbach’s alpha for internal consistency of the Persian version of STAI-Y was 0.846 for state anxiety and 0.886 for trait anxiety. Also, the reliability and internal consistency were good (30).

**Secondary outcomes**

The secondary outcomes included treatment compliance and treatment satisfaction. Treatment compliance for psychotherapy group was defined as the mean number of attendance of the participants in the CBT sessions (from 10 sessions). Treatment adherence for pharmacotherapy was defined as the mean number of formal contact sessions with a psychiatric (from 5 sessions through phone or visit in our infertility clinic). For treatment satisfaction, the participants answered to a question and rated their feeling about the program from 1 (very low satisfaction) to 5 (very high satisfaction).

**Statistical analysis**

To examine participants’ demographic characteristics, cross-tabulations stratified by three groups were used. ANOVA tests were applied to examine group differences in clinical characteristics at baseline. Also, t test and Chi Square test were applied to examine differences in adherence or satisfaction between the CBT and sertraline groups.

We used intention-to-treat analysis to manage the missing outcomes via multiple imputation chained technique (MICE). For the participants, linear mixed models with random intercepts, time, treatment group, and time-group interaction as fix factors were used to estimate each outcome measure in the our groups. Pairwise contrasts were used to compare group differences in the pre-to-post and pre-to-follow-up outcome scores. Also, pooled standard deviation adjusted for sample size (Hedges’ g) was employed to examine the effect sizes. The effect sizes were defined as small (g=0.20), medium
(g=0.50), and large (g=0.80) (31). The data were analyzed using statistical package for the social sciences (SPSS) software version 18.0 (SPSS Inc., Chicago, IL., USA). We considered P<0.05 as significant.

Results

Baseline demographic and clinical characteristics

Of 60 women who entered the trial, 50 completed the trial from baseline to post-trial and follow-up (CBT group: n=19, sertraline group: n=13, control group: n=18). Figure 1 reveals the recruitment of the participants from the beginning of the study to post-trial and follow-up.

Table 2 describes the demographic characteristics of the participants in three groups of the trial. The women, aged 31.7 years (± SD=5.9). The majority of them had high school or university level of education. There were no significant differences with respect to age, education, infertility duration, and the number of miscarriages among these three groups.
Table 2: Demographic characteristics of the population study

| Variables          | CBT         | Sertraline | Control  | All patients |
|--------------------|-------------|------------|----------|--------------|
| Age (Y)            | 32.7 ± 6.8  | 30.2 ± 4.9 | 32.2 ± 5.8 | 31.7 ± 5.9  |
| Education (Y)      |             |            |          |              |
| <12                | 10 (50)     | 10 (50)    | 6.0 (30) | 26 (43.3)    |
| ≥12                | 10 (50)     | 10 (50)    | 14 (70)  | 34 (46.7)    |
| Job                |             |            |          |              |
| Employee           | 1.0 (5)     | 2.0 (10)   | 2.0 (10) | 5.0 (8.3)    |
| Unemployed         | 19 (95)     | 18 (90)    | 18 (90)  | 55 (81.7)    |
| Number of abortion |             |            |          |              |
| 2                  | 9.0 (45)    | 10 (50)    | 11 (55)  | 20 (33.3)    |
| 3                  | 5.0 (25)    | 5.0 (25)   | 4.0 (20) | 14 (23.3)    |
| ≥4                 | 6.0 (30)    | 5.0 (25)   | 5.0 (25) | 26 (43.4)    |
| Duration of infertility (month) | 69.6 ± 54.3 | 34.9 ± 8.2 | 60.6 ± 56.1 | 64.4 ± 49.0 |

Data are presented as mean ± SD or n (%). CBT; Cognitive behavior therapy.

Table 3: Within group effect sizes of the interventions from pre-treatment to post-treatment and follow-up in three groups of the trials

| Outcomes                          | Description | Pre-treat | Post-treat | Follow-up | Within group effect size pre-treat with post-treat | Within group effect size pre-treat with follow-up |
|-----------------------------------|-------------|-----------|------------|-----------|--------------------------------------------------|--------------------------------------------------|
| **Depression**                    |             |           |            |           |                                                  |                                                  |
| CBT                               | 23.1 ± 9.89 | 13.4 ± 12.2 | 16.1 ± 11.4 | 0.84 (0.30, 1.37) | 0.54 (-0.01, 1.11) |
| Sertraline                        | 23.4 ± 9.9  | 14.7 ± 10.2 | 22.9 ± 9.2  | 1.03 (0.53, 1.53) | 0.08 (-0.21, 0.37) |
| Control                           | 24.4 ± 8.1  | 24.2 ± 9.5  | 24.1 ± 9.5  | 0.02 (-0.30, 0.36) | 0.04 (-0.29, 0.38) |
| Anxiety                           |             |           |            |           |                                                  |                                                  |
| CBT                               | 29.4 ± 7.3  | 45.4 ± 7.3  | 47.0 ± 6.7  | 0.42 (-0.15, 1.00) | 0.25 (-0.35, 0.85) |
| Sertraline                        | 51.5 ± 6.0  | 43.6 ± 5.6  | 46.9 ± 5.1  | 1.21 (0.58, 1.84) | 0.83 (0.31, 1.35) |
| Control                           | 47.5 ± 9.0  | 51.0 ± 8.5  | 50.2 ± 6.5  | -0.38 (-0.86, 0.10) | -0.25 (-0.87, 0.36) |
| Infertility stress social concern |             |           |            |           |                                                  |                                                  |
| CBT                               | 34.9 ± 9.7  | 32.4 ± 9.8  | 30.6 ± 9.7  | 0.17 (-0.50, 0.85) | 0.31 (-0.35, 0.97) |
| Sertraline                        | 29.5 ± 8.3  | 28.2 ± 8.4  | 30.0 ± 6.9  | 0.16 (-0.23, 0.56) | -0.09 (-0.62, 0.43) |
| Control                           | 30.0 ± 9.7  | 33.1 ± 11.5 | 35.8 ± 12.1 | -0.23 (-0.73, 0.26) | -0.46 (-0.96, 0.04) |
| Sexual concern                    |             |           |            |           |                                                  |                                                  |
| CBT                               | 27.8 ± 7.6  | 24.4 ± 9.7  | 23.8 ± 9.6  | 0.28 (-0.32, 0.90) | 0.28 (-0.42, 1.00) |
| Sertraline                        | 24.2 ± 9.0  | 21.3 ± 8.8  | 23.7 ± 6.5  | 0.32 (-0.14, 0.79) | 0.06 (-0.39, 0.53) |
| Control                           | 22.9 ± 7.3  | 26.1 ± 8.9  | 26.0 ± 10.6 | -0.40 (-0.84, 0.03) | -0.28 (-0.82, 0.25) |
| Relationship concern              |             |           |            |           |                                                  |                                                  |
| CBT                               | 35.9 ± 8.9  | 29.9 ± 9.3  | 30.5 ± 8.4  | 0.42 (-0.28, 1.13) | 0.41 (-0.27, 1.10) |
| Sertraline                        | 32.4 ± 10.0 | 29.4 ± 8.6  | 28.3 ± 6.8  | 0.36 (-0.05, 0.77) | 0.52 (0.08, 0.95) |
| Control                           | 30.2 ± 8.8  | 34.5 ± 8.7  | 34.5 ± 10.2 | -0.50 (-0.96, -0.03) | -0.40 (-0.92, 0.12) |
| Reject of life without parent      |             |           |            |           |                                                  |                                                  |
| CBT                               | 30.9 ± 9.8  | 26.9 ± 9.8  | 27.5 ± 9.0  | 0.35 (-0.16, 0.87) | 0.30 (-0.23, 0.84) |
| Sertraline                        | 23.3 ± 5.9  | 23.6 ± 4.8  | 28.6 ± 6.2  | -0.06 (-0.43, 0.31) | -0.75 (-1.32, 0.18) |
| Control                           | 31.1 ± 7.8  | 33.9 ± 7.3  | 32.2 ± 6.7  | -0.63 (-0.96, -0.30) | 0.94 (-1.34, -0.54) |
| Need for parenthood               |             |           |            |           |                                                  |                                                  |
| CBT                               | 35.9 ± 12.4 | 29.5 ± 10.4 | 26.6 ± 9.7  | 0.58 (0.11, 1.05) | -0.03 (-0.69, 0.62) |
| Sertraline                        | 38.7 ± 9.8  | 35.6 ± 10.1 | 39.2 ± 9.7  | 0.36 (-0.03, 0.77) | -0.05 (-0.40, 0.28) |
| Control                           | 39.5 ± 9.5  | 39.3 ± 11.3 | 44.0 ± 10.3 | 0.02 (-0.31, 0.37) | -0.65 (-1.02, -0.28) |
| Total score                       |             |           |            |           |                                                  |                                                  |
| CBT                               | 165.6 ± 36.4| 143.1 ± 34.3| 149.1 ± 31.9| 0.42 (-0.24, -1.10)| 0.30 (-0.39, -1.01)|
| Sertraline                        | 148.3 ± 34.6| 138.2 ± 33.5| 150.12 ± 9.0| 0.34 (-0.05, 0.74) | -0.06 (-0.47, 0.35) |
| Control                           | 154.1 ± 23.2| 163.3 ± 42.7| 175.6 ± 40.0| -0.25 (-0.70, 0.19) | -0.61 (-1.10, -0.11) |

Data are presented as mean ± SD or n (%). Rang scores: Depression, 0-63; State anxiety, 20-80; Trait anxiety, 20-80; Social concern (1-60), sexual concern (1-48), relationship concern (1-60), rejection of life without child (1-48), need for parenthood (1-60), total scores of infertility stress (46-276). CBT; Cognitive behavioral therapy. * Linear mixed models with random intercept time, treatment group, and time-group interaction as fix factors were used to estimate each outcome measure in three groups of the trial, P<0.05. The effect sizes (Hedges’ g) were defined as small (g=0.20), medium (g=0.50), and large (g=0.80).
Treatment outcomes

Depression

In the CBT group, the score of depression, decreased more significantly in the post-trial than pre-trial with a large effect size \( [g (95\% CI)=0.84 (0.30, 1.37)] \) and at follow-up over pre-trial with a moderate effect size \( [g (95\% CI)=0.54 (0.14, 1.11)] \). In the sertraline group, the depression symptoms diminished more significantly at post-trial than at pre-trial with a large effect size \( [g (95\% CI)=1.03 (0.53, 1.53)] \). In the control group, the depression symptoms did not change significantly from pre-trial to post-trial and also, in the follow-up (Table 3).

There were significant group-time interactions for the severity of depression symptoms according to the BDI-II \( [F (4, 196.08)=4.96, P=0.001] \). CBT decreased the depression symptoms more significantly, while the sertraline group showed a moderate effect size at the post-trial \( [g (95\% CI)=0.11(-0.03, -0.50)] \) and large effect size at follow-up \( [g (95\% CI)=-1.60 (-1.31, -0.03)] \). The depression, diminished more significantly in the CBT group than in the control group with a large effect size at the post-trial \( [g (95\% CI)=1.00(-1.66, -0.27)] \) and follow-up \( [g (95\% CI)=0.78 (-1.42, -0.11)] \). Also, in the sertraline group, we observed a significant decrease in the depression symptoms in comparison with the control group, with a large effect size at the post-trial \( [g (95\% CI)=0.97 (-1.63, -0.32)] \), but not at follow-up (Table 4).

In the CBT and control groups, anxiety scores did not change significantly at post-trial than pre-trial and also, at follow-up in comparison with pre-trial. In the sertraline group, the score of anxiety dropped more significantly at post-trial than at pre-trial with a large effect size \( [g (95\% CI)=1.21 (0.48, 1.84)] \) and at follow-up in comparison with pre-trial with a large effect size \( [g (95\% CI)=0.83 (0.31, 1.35)] \).

There were significant group-time interactions among three groups for the severity of anxiety symptoms, according to state-anxiety \( [F (4, 174.33)=5.20, P=0.001] \). There were no significant differences between the CBT group and the sertraline group in reducing the anxiety at post-trial and at follow-up. The scores of state-anxiety did not change significantly in the CBT group over the control group at post-trial and follow-up. Sertraline group lowered the scores of state-anxiety more significantly than the control group did with a large effect size of the post-trial \( [g (95\% CI)=1.04 (-1.70, -0.38)] \), but not follow-up.

Infertility stress

In the CBT group, the total score of infertility stress diminished more considerably at post-trial with a moderate effect size \( [g (95\% CI)=0.42 (-0.24, -1.10)] \) and at follow-up with a moderate effect size \( [g (95\% CI)=0.32 (-0.39, -1.01)] \). Of five subscales of FPI, CBT group showed the ‘need to parenthood concerns’ scale more considerably at post-trial with a moderate effect size \( [g (95\% CI)=0.58 (0.11, 1.05)] \) and at follow-up in comparison with pre-trial with a moderate effect size \( [g (95\% CI)=0.30 (-0.39, -1.01)] \). The CBT group showed a more significant decrease in the total scores of infertility stress in comparison with the sertraline group, with a large, small size at follow-up \( [g (95\% CI)=0.03 (-0.65, -0.58)] \).

In the sertraline group, the total score of infertility stress did not change significantly at post-trial and follow-up. Of five subscales of FPI, only the sertraline group showed a decrease in scores of ‘marital relationship concerns’ more considerably in the post-trial with a moderate effect size \( [g (95\% CI)=0.52 (0.08, 0.95)] \).

In the control group, the total score of infertility stress and the social concerns did not change considerably in the post-trial, but those scores increased significantly at post-trial and follow-up. The CBT group over the control group at post-trial and follow-up. The total score of infertility stress did not change significantly at post-trial and follow-up. The scores of state-anxiety did not change significantly in the CBT group over the control group at post-trial and follow-up. Sertraline group lowered the scores of state-anxiety more significantly than the control group did with a large effect size of the post-trial \( [g (95\% CI)=1.04 (-1.70, -0.38)] \), but not follow-up.

| Outcomes          | CBT and Sertraline* | CBT and Control** | Sertraline and Control† |
|-------------------|---------------------|-------------------|-------------------------|
|                   | Post | Follow up | Post | Follow up | Post | Follow up |
| Anxiety           | -0.11 (-0.73, -0.50) | -0.67 (-1.31, -0.03) | -1.00 (-1.66, -0.27) | -0.78 (-1.42, -0.11) | -0.97 (-1.63, -0.32) | -0.13 (-0.75, 0.48) |
| Infertility stress| 0.27 (0.34, 0.09)    | 0.02 (-0.59, 0.64)  | -0.72 (-1.36, 0.11) | -0.50 (-1.13, 0.18) | -1.04 (-1.70, -0.38) | -0.59 (-1.22, 0.04) |
| Social concern    | 0.46 (-0.16, 1.09)   | 0.03 (-0.58, 0.65)  | -0.06 (-0.68, 0.53) | -0.48 (-1.11, -0.10) | -0.49 (-1.12, 0.13) | -0.57 (-1.20, 0.05) |
| Sexual concern    | 0.34 (-0.27, 0.96)   | 0.01 (-0.60, 0.63)  | -0.18 (-0.81, 0.65) | -0.22 (-0.84, 0.11) | -0.55 (-1.18, 0.07) | -0.27 (-0.89, 0.35) |
| Relationship      | 0.05 (-0.56, 0.67)   | 0.29 (-0.32, 0.91)  | -0.52 (-1.15, -0.08) | -0.44 (-1.07, 0.12) | -0.59 (-1.22, 0.03) | -0.73 (-1.38, -0.09) |
| Reject of parenthood| 0.44 (-0.18, 1.06)  | -0.13 (-0.75, 0.48) | -0.82 (-1.47, 0.09) | -0.99 (-1.64, -0.10) | -1.70 (-2.42, -0.98) | -1.05 (-1.71, -0.39) |
| Need to parenthood| -0.61 (-1.24, 0.02) | -0.27 (-0.89, 0.34) | -0.92 (-1.58, -0.34) | -0.75 (-1.39, -0.14) | -0.35 (0.08, 0.26)  | -0.49 (-1.11, 0.13) |
| Total scores      | 0.14 (-0.47, 0.77)   | -0.03 (-0.65, -0.58) | -0.53 (-1.16, -0.18) | -0.74 (-1.38, -0.33) | -0.67 (-1.30, -0.03) | -0.74 (-1.38, -0.10) |

Data are presented as g (95% CI). CI: Confidence interval; CBT: Cognitive behavioral therapy. * *, Linear mixed models with random intercept time, treatment group, and time-group interaction as fixed factors were used to estimate each outcome measure in three groups of the trial. **, P<0.05. The effect sizes (Hedges’ g) were defined as small \((g=0.20)\), medium \((g=0.50)\), and large \((g>0.80)\).
There were significant group-time interactions between three groups for the total score of infertility stress, according to FPI [F (4, 2097.24)=2.97, P=0.022)]. Also, there were significant group-time interactions for two subscales of FPI, including marital concern [F (4, 189.6)=3.05, P=0.008)] and rejection of parenthood [F (4, 127.23)=4.15, P=0.004)]. The CBT group had a reduction at total scores of infertility stress more considerable than the sertraline group, with a large, small size at follow up [g (95% CI)=-0.03 (-0.65, -0.58)]. The CBT group had a reduction in the infertility stress scores more than the control group, with a large effect size in the post-trial [g (95% CI)=0.53 (-1.16, -0.18)] and follow-up [g (95% CI)=0.74 (-1.38, -0.33)]. Also, sertraline group showed less infertility stress than the control group, with a large effect size at the post-trial [g (95% CI)=0.67 (-1.30, -0.03)] and follow-up [g (95% CI)=0.74 (-1.38, -0.10)]. The CBT group had a decrease at scores of “the need to parenthesis of infertility stress” more than the control group, with a large effect size at the post-trial [g (95% CI)=-0.92 (-1.58, -0.34)] and follow-up [g (95% CI)=-0.75 (-1.39, -0.14)]. Also, CBT group had a reduction in scores of ‘rejection of parenthood’ more than the control group did at follow-up with a large effect size [g (95% CI)=-0.99 (-1.64, -0.10)]. The sertraline group also had a reduction at scores of the following subscales of infertility stress more than control did; social concerns at post-trial with a moderate effect size [g (95% CI)=0.49 (-1.12, -0.13)], marital relationship concerns at follow-up with a large effect size [g (95% CI)=0.73 (-1.38, -0.09)], and rejection of parenthood with a moderately small size of post-trial [g (95% CI)=1.70 (2.42, -0.98)] and follow-up [g (95% CI)=0.49 (-1.11, -0.13)].

Secondary outcomes

Treatment compliance

Dropout rates were 5% (19/20) in the CBT group, 35% (13/20) in the sertraline arm, and 10% (18/20) in the usual care group. Out of 20 women of the CBT group, 19 persons provided post-trial (95%) and follow-up data (95%). 17 women of the sertraline group, (17/20, 85%) provided post-trial and 13 persons (65%) provided follow-up data. Women in the CBT group were more likely than those in the sertraline group to complete trial at the follow-up assessments [g(2)=5.625, P=0.02; OR (95% CI)=1.46 (1.04, 2.04)]. The CBT group (n=15/20) attended 8.10 ± 1.83 sessions (mean ± SD) from 10 sessions (with the psychologist), (75% compliance). The mean number of sertraline sessions contacted with the psychiatrists was 2.60 (SD 1.23) from 5 sessions of formal contact with psychiatric. Also, 11 women of the sertraline group contacted with psychiatrist 3 to 5 sessions of formal contract for the treatment (55% compliance).

Treatment satisfaction

The mean score treatment satisfaction of the participations in the CBT group was very significantly higher (4.26 ± 0.99, rated; 1-5) than the scores of those treatment satisfaction with sertraline group (2.12 ± 1.08, t=6.081, P<0.001).

Discussion

Here, we compared the efficacy of psychotherapy with pharmacotherapy in improving depression, anxiety, and pregnancy stress of depressed infertile women with RPL. We found that both CBT and sertraline led to moderate to large improvements in the scores of depression and infertility stress in these women. Regarding depression amelioration, both CBT and sertraline were superior to the control group, and CBT was superior to sertraline, with a moderate to large effect size of post-trial and follow-up.

This study has been the first RCT to compare the effect of CBT with sertraline in depressed infertile women with RPL history, therefore, we could not find any research to use sertraline in the treatment of depression in the RPL women. Although, there was an RCT that had compared the effect of CBT vs. sertraline in the diabetic patients who suffered from major depression. They reported that both CBT and sertraline improved the depression in their patients, with a superiority for sertraline (32).

In line with our results, Nakano et al. (14) investigated the effect of individual CBT on the 14 patients with RLP and depression/anxiety. They observed that CBT was useful in the improving the scores of depressions based on the BDI-II measurement. Although in both studies, CBT reduced the depression of women, there have been differences between our study and Nakano’ study. Respectively, these differences include: population (the infertile women of vs. non infertile women), the number of groups in the study (three groups, including CBT, sertraline, and control vs. one group, only CBT), and the design of the study (RCT vs. interventional study with pretest-posttest design).

The important question of these results is that how the efficacy of CBT in the treatment of depression, persisted until 3-month follows-up against sertraline. There are some assumptions. First, in psychotherapies such as CBT, the thoughts can be altered, which may be persisted for a long time or even forever. Secondly, the CBT group had more treatment adherence in comparison with the sertraline group. The attendance and cooperation in the treatment of CBT group were greater than the sertraline group. The attendance and cooperation in the treatment of CBT group were greater than the sertraline group. The attendance and cooperation in the treatment of CBT group were greater than the sertraline group.

In the present study, sertraline, showed a reduce score of anxiety more significantly than the control group, with a large effect size at post-trial, but not at follow-up. There were no significant differences between CBT
and sertraline in reducing the anxiety at post-trial and at follow-up. Inconsistent with our results, a study reported that CBT reduced the anxiety of depressed women with RPL (14). Also, results of a systematic review reported that psychological support and interventions may reduce levels of stress, anxiety or depression on subsequent pregnancy of women with a miscarriage history (33). Our previous RCTs also revealed that CBT was an efficient approach in reducing the anxiety in infertile women (18, 34).

It is important to explain why CBT did not improve the anxiety of infertile women. It may be related to the treatment approach. First, we used a model of CBT enhanced with FACBT which emphasized infertility-specific stress, rather than general anxiety. Secondly, the focuses of therapy were treatment of depression, not anxiety symptoms. Finally, the practices for anxiety improvement were minor. Wenzel (35) suggested that interventional strategies such as cognitive restructuring, behavioral activation and mindfulness are essential in the patients with RPL. Focus on improving anxiety along with the depression is recommended for future psychotherapies research.

In the present study, CBT reduced the total scores of infertility stress more considerably than sertraline, with a large, small size at follow-up, but not at post-trial. Both CBT and sertraline were superior to the control group in mitigating infertility stress. We propose two assumptions. First, considering the mean value of infertility stress of depressed the infertile women at the baseline, we found that the mean level of infertility stress in the CBT group was higher than the sertraline group (165 ± 36.4 vs. 148.3 ± 34.3, respectively) in pre-treatment. Although, both CBT and sertraline reduced the total score of infertility stress at the post-treatment (138 ± 33.5 vs. 149.1 ± 34.3, respectively), this reduction was not considerable at post-trial. When the infertility stress mitigation in the CBT group continued to the follow-up, the different effect of CBT and sertraline would be significant. Secondly, as the effectiveness of CBT was required for practice of skills, reducing symptoms of the infertility stress in CBT lasted longer compared with sertraline.

Note that in this study, both CBT and sertraline changed only in the some subscales of infertility stress. For explaining these effects, we propose three reasons. First, considering the mean scores and range of scores at baseline, it is found that the mean of these two subscales was higher than that of the three others infertility subscales from the beginning. Secondly, the main effect of CBT and sertraline in mitigating infertility stress, especially the total score of the FPI, was on reducing “rejection of life without parenthood” and “need to parenthood”. Third, these subscales are very important in the infertile women with RPL history in comparison with the control group. And, two subscales of FPI “rejection of life without parenthood” and “need to parenthood” increased in post-trial and follow-up.

These findings have particularly important clinical implications for gynecologists, psychiatrists, and psychologist. This study suggests that both CBT and sertraline are sufficient in the reducing depression and infertility stress of infertile women with RPL, history with a significant advantage favoring CBT. On the other hand, sertraline was superior to CBT in mitigating the anxiety score. The CBT group showed greater adherence and satisfaction with the treatment than sertraline. Further study is required to investigate how to increase the adherence and satisfaction with pharmacotherapy in the infertile women with RPL.

While these findings are promising, there are some limitations to be noted. First, the disproportional number of dropouts from the CBT group and sertraline group was not addressed well. The dropouts of the pharmacotherapy were high. Of the six participants who discontinued taking sertraline, three patients explained that they experienced side effects such as agitation, nausea, and vomiting. Also, three other patients did not respond to our contacts with phone or social networks such as WhatsApp. Further research is required to assess the obstacles against infertile women with RPL history that taking anti-depressants medicine. Moreover, our results were provided from one infertility clinic of a small city. A multicenter study is a better choice for further studies. In addition, further research is needed to evaluate other psychotherapy interventions and other antidepressant effect on the anxiety and depression in this patients. Confirming our findings, require to test potential moderators influencing psychotherapy or sertraline response, and address an acceptance of therapy model.

**Conclusion**

This study provided preliminary support for the efficacy of CBT and sertraline therapy for infertile women with RPL history and offered a range of further research opportunities in this field. Future research is also necessary to demonstrate whether routine CBT/pharmacotherapy adjoined with treatments of ART would prevent the negative psychological consequences in these patients. Assessing whether adding CBT or sertraline to therapies is cost-effective for the treatment of depressed infertile women with RPL is also another research area.

**Acknowledgments**

We would like to thank all of volunteer participants in our study, and our clinical cooperators who invited them. We also thank Sharareh Abedi Firoozjai and Shiva Shafie Rizi, for conducting the CBT sessions. The Deputy Research of Babol University of Medical Sciences supported the funding (grant number: 9135022). The authors declare no conflict of interest.

**Authors’ Contributions**

M.F.; Participated in study design, drafted the manuscript. F.Kh.; Was responsible for overall supervision, revised the drafted manuscript. Z.B., S.E.; Conducted project managing. S.Kh.; Contributed extensively in interpretation.
of the data and the conclusion. Z.T.; Contributed to data gathering. All authors contributed to the drafting of this manuscript and approved the final.

References
1. van Dijk MM, Kolte AM, Limpens J, Kirk E, Quenby S, van Wely M, et al. Recurrent pregnancy loss: diagnostic workup after two or three pregnancy losses? A systematic review of the literature and meta-analysis. Hum Reprod Update. 2020; 26(3): 356-367.
2. Rasmussen A, Matthiesen L, Rylander R, Christiansen OB. Is the incidence of recurrent pregnancy loss increasing? A retrospective register-based study in Sweden. Acta Obstet Gynecol Scand. 2017; 96(11): 1365-1372.
3. Adib Rad H, Basirat Z, Mostafazadeh A, Faramarzi M, Bajani A, Nouri HR, et al. Evaluation of peripheral blood NK cell subsets and cytokines in unexplained recurrent miscarriage. J Chin Med Assoc. 2018; 81(12): 1065-1070.
4. Tamhankar VA, Liu B, Yan J, Li TC. A comparison of pattern of pregnancy loss in women with infertility undergoing IVF and women with unexplained recurrent miscarriages who conceive spontaneously. Obstet Gynecol. 2015; 2015: 989454.
5. Pasha H, Basirat Z, Esmaizadeh S, Faramarzi M, Adibrad H. Marital intimacy and predictive factors among infertile women in northern Iran. J Clin Diagn Res. 2017; 11(6): QC13-QC17.
6. Basirat Z, Faramarzi M, Esmaeizadeh S, Abedi Firoozjai SH, Mahouti T, Geraili Z. Stress, depression, sexual function, and alexithymia in infertile females with and without polycystic ovary syndrome: a case-control study. Inf J Fertil Steril. 2019; 13(3): 203-208.
7. Zafir Golzar Yazdi H, Aghamohammadian Sharbaf H, Kareshti H, Amirian M. Infertility and psychological and social health of Iranian infertile women: a systematic review. Iran J Psychiatri. 2020; 15(1): 67-79.
8. Kiani Z, Simbar M, Hajan S, Zayen F. The prevalence of depression symptoms among infertile women: a systematic review and meta-analysis. Fertil Res Pract. 2021; 7(1): 6.
9. Karaca A, Unsal G. Psychosocial problems and coping strategies among Turkish women with infertility. Asian Nurs Res (Korean Soc Nurs Sci). 2015; 9(3): 243-250.
10. Haghparast E, Faramarzi M, Hassanzadeh R. Psychiatric symptoms and pregnancy distress in subsequent pregnancy after spontaneous abortion history. Pak J Med Sci. 2016; 32(5): 1097-1101.
11. Adib-Rad H, Basirat Z, Faramarzi M, Mostafazadeh A, Bajani A. Psychological distress in women with recurrent spontaneous abortion: a case-control study. Turk J Obstet Gynecol. 2019; 16(3): 151-157.
12. Wang HY, Qiao J, Sun XK, Wang SY, Liang XY, Sun Y, et al. Epidemiological survey and risk factor analysis of recurrent spontaneous miscarriages in infertile women at large infertility centers. Chin Med J (Engl). 2017; 130(17): 2056-2062.
13. Faramarzi M, Khirghah F, Esmaieizadeh S, Allipour A, Hajihamadi M, Rahnama J. Is psychotherapy a reliable alternative to pharmacotherapy to promote the mental health of infertile women? A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2008; 141(1): 49-53.
14. Nakano Y, Akechi T, Furukawa TA, Sugiura-Ogasawara M. Cognitive behavior therapy for psychological distress in patients with recurrent miscarriage. Psychol Res Behav Manag. 2013; 6: 37-43.
15. Patel A, Dinesh N, Sharma PSVN, Kumar P, Binu VS. Outcomes of structured psychotherapy for emotional adjustment in a childless couple diagnosed with recurrent pregnancy loss: a unique investigation. J Hum Reprod Sci. 2018; 11(2): 202-207.
16. Séjourné N, Callahan S, Chabrol H. The utility of a psychological intervention for coping with spontaneous abortion. J Reprod Infant Psychol. 2010; 28(3): 287-296.
17. Barat S, Yazdani S, Faramarzi M, Khafi S, Darvish M, Rad MN, et al. The effect of brief supportive psychotherapy on prevention of psychiatric morbidity in women with miscarriage: a randomized controlled trial about the first 24-hours of hospitalization. Oman Med J. 2020; 35(3): e1130.
18. Kjaersgaard MI, Parner ET, Vestergaard M, Sørensen MJ, Olsen J, Christensen J, Bech BH, Pedersen LH. Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study. PLoS One. 2013; 8(8): e72095.
19. Beck AT, Velez Edwards DR, Gorondo P, Sundermann AC, Torstenson ES, Jones SH, et al. Association between first trimester antidepressant use and risk of spontaneous abortion. Pharmacotherapy. 2019; 39(9): 889-898.
20. Sugiura-Ogasawara M, Furukawa TA, Nakano Y, Hori S, Aoki K, Kitamura T. Depression as a potential causal factor in subsequent miscarriage in recurrent spontaneous aborters. Hum Reprod. 2002; 17(10): 2580-2584.
21. Jeve YB, Davies W. Evidence-based management of recurrent miscarriages. J Hum Reprod Sci. 2014; 7(3): 159-69.
22. First MB, Williams JBW, Karg RS, Spitzer RL. User's guide for the SCID-5-CV structured clinical interview for DSM-5® disorders: Clinical version. APA; 2016. Available from https://www.appi.org/products/interviewing/users-guide-for-the-structured-clinical-interv-
23. Basirat Z, Faramarzi M, Chehrazi M, Amiri M, Gholiforou F, Tajalli Z. Differences between infertile women with and without PCOS in terms of anxiety, coping styles, personality traits, and social adjustment: a case-control study. Arch Gynecol Obstet. 2020; 301(2): 619-626.
24. Kohlenberg RJ, Tsai M. Functional analytic psychotherapy: Creating intense and curative therapeutic relationships. Boston, USA: Springer; 1991.
25. Newton CR, Sherrard W, Glavac I. The Fertility Problem Inventory: measuring perceived infertility-related stress. Fertil Steril. 1999; 72(1): 54-62.
26. Beck AT, Steer RA, Brown GK. Beck depression inventory-II. San Antonio. 1996; 78(2): 490-498.
27. Ghassemzadeh H, Mojtahab R, Karamghadri N, Ebrahimkhani N. Psychometric properties of a Persian-language version of the beck depression inventory–second edition: BDII-PERSIAN. Depress Anxiety. 2005; 21(4): 185-192.
28. Samani RO, Almasi-Hashemi A, Shokri F, Maroufizadeh S, Vesali S, Sepidarkish M. Validation study of the fertility problem inventory in Iranian infertile patients. Middle East Fertil Soc J. 2017; 22(1): 48-53.
29. Spielbergber CD, Vagg PR, Barker LR, Donham GW, Westberry LG. The factor structure of the state-trait anxiety inventory. Stress and anxiety. Washington, DC: Hemisphere. 1980.
30. Abdoli N, Farnia V, Salemi S, Davarinejad O, Ahmadi Jouybari T, Kheirani M, et al. Reliability and validity of persian version of state-trait anxiety inventory among high school students. East Asian Arch Psychiatry. 2020; 30(2): 44-47.
31. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Lawrence Erbaum Associates; 1988: 20-26.
32. Petrak F, Herertz S, Albus C, Hermanns N, Hiemke C, Hiller W, et al. Cognitive behavioral therapy versus sertraline in patients with depression and poorly controlled diabetes: the diabetes and depression (DAD) study: a randomized controlled multicenter trial. Diabetes Care. 2015; 38(5): 767-775.
33. San Lazaro Campillo I, Meaney S, Mcnamara K, O'Donoghue K. Psychological and support interventions to reduce levels of stress, anxiety or depression on women's subsequent pregnancy with a history of miscarriage: an empty systematic review. BMJ Open. 2017; 7(9): e017802.
34. Pasha H, Faramarzi M, Esmaizadeh S, Kheirkhah F, Salmalian H. Comparison of pharmacological and nonpharmacological treatment strategies in promotion of infertility self-efficacy scale in infertile women: a randomized controlled trial. Iran J Reprod Med. 2013; 11(6): 495-502.
35. Wenzel A. Cognitive behavioral therapy for pregnancy loss. Psychotherapy (Chic). 2017; 54(4): 400-405.